ANAB – anaptysbio, inc. (US:NASDAQ)
Stock Stats
News
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer [Yahoo! Finance]
Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16% [Yahoo! Finance]
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Form 8-K ANAPTYSBIO, INC For: Jun 12
Form 4 ANAPTYSBIO, INC For: May 22 Filed by: MULROY DENNIS
Form 10-Q ANAPTYSBIO, INC For: Mar 31
Form 8-K ANAPTYSBIO, INC For: May 09
Form SC 13G ANAPTYSBIO, INC Filed by: Frazier Life Sciences Public Fund, L.P.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.